Literature DB >> 21516514

Pre- and post-translational regulation of osteopontin in cancer.

Pieter H Anborgh1, Jennifer C Mutrie, Alan B Tuck, Ann F Chambers.   

Abstract

Osteopontin (OPN) is a matricellular protein that binds to a number of cell surface receptors including integrins and CD44. It is expressed in many tissues and secreted into body fluids including blood, milk and urine. OPN plays important physiological roles in bone remodeling, immune response and inflammation. It is also a tumour-associated protein, and elevated OPN levels are associated with tumour formation, progression and metastasis. Research has revealed a promising role for OPN as a cancer biomarker. OPN is subject to alternative splicing, as well as post-translational modifications such as phosphorylation, glycosylation and proteolytic cleavage. Functional differences have been revealed for different isoforms and post-translational modifications. The pattern of isoform expression and post-translational modification is cell-type specific and may influence the potential role of OPN in malignancy and as a cancer biomarker.

Entities:  

Year:  2011        PMID: 21516514      PMCID: PMC3088790          DOI: 10.1007/s12079-011-0130-6

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  120 in total

Review 1.  Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications.

Authors:  R J Collighan; M Griffin
Journal:  Amino Acids       Date:  2008-11-04       Impact factor: 3.520

Review 2.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

3.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

4.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

5.  A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.

Authors:  Hao Liu; Anmin Chen; Fengjing Guo; Lin Yuan
Journal:  Cancer Lett       Date:  2010-03-06       Impact factor: 8.679

6.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

Review 7.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

8.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

9.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

View more
  53 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

3.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

4.  Phosphorylation of osteopontin has proapoptotic and proinflammatory effects on human knee osteoarthritis chondrocytes.

Authors:  Shu-Guang Gao; Yang Yu; Chao Zeng; Shi-Tao Lu; Jian Tian; Chao Cheng; Liang-Jun Li; Guang-Hua Lei
Journal:  Exp Ther Med       Date:  2016-10-05       Impact factor: 2.447

Review 5.  New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases.

Authors:  Jessica A Williams; Sharon Manley; Wen-Xing Ding
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 6.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Authors:  Thomas E Kruger; Andrew H Miller; Andrew K Godwin; Jinxi Wang
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-07       Impact factor: 6.312

7.  Spp1 (osteopontin) promotes TGFβ processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases.

Authors:  Irina Kramerova; Chino Kumagai-Cresse; Natalia Ermolova; Ekaterina Mokhonova; Masha Marinov; Joana Capote; Diana Becerra; Mattia Quattrocelli; Rachelle H Crosbie; Ellen Welch; Elizabeth M McNally; Melissa J Spencer
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

8.  Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Authors:  K D M Nakamura; T M Tilli; J L Wanderley; A Palumbo; R M Mattos; A C Ferreira; C E Klumb; L E Nasciutti; E R Gimba
Journal:  Tumour Biol       Date:  2015-09-24

9.  WFDC1 is a key modulator of inflammatory and wound repair responses.

Authors:  Steven J Ressler; Truong D Dang; Samuel M Wu; Dennis Y Tse; Brian E Gilbert; Annapurna Vyakarnam; Feng Yang; Isaiah G Schauer; David A Barron; David R Rowley
Journal:  Am J Pathol       Date:  2014-09-16       Impact factor: 4.307

Review 10.  OPN -Revisited.

Authors:  Vijayanirmala Subraman; Muthukumar Thiyagarajan; N Malathi; Sharada T Rajan
Journal:  J Clin Diagn Res       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.